ClinicalTrials.gg
RecruitingNCT07191249SUNFLOWUpdated Aug 11, 2026

Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .

A Phase 2 interventional study of Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells. in Follicular Lymphoma, sponsored by Tel-Aviv Sourasky Medical Center. Recruiting at 4 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Tel-Aviv Sourasky Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Lymphoma, Follicular with a site in Israel — 9 open to participants now, 22 under way, 9 of them phase 3. Lymphoma, Follicular · Israel.

Planned enrollment
39th of 48
40 · median 250
Started
2026
with 3 others
Phase 2
8 of 51
2 open now
Primary completion
2028-04
later than 11 of 21 live
Registered
47th of 51
by date

Among the 51 studies in Lymphoma, Follicular with a site in Israel, this one is the 39th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 11 of the 21 other live ones, and was the 47th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

9 of the 51 studies in Lymphoma, Follicular with a site in Israel are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Lymphoma, Follicular with a site in Israel, or all of them as a file.
02

Study summary

This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.

Read the detailed description

Eligible patients will undergo screening and, upon signing an Informed Consent Form, will receive their first dose of SC Mosunetuzumab.

Mosunetuzumab is administered via SC injection without the need for mandatory hospitalization. The first cycle lasts 21 days, followed by subsequent 21-day cycles. In Cycle 1, Mosunetuzumab is given on Day 1 (5 mg), Day 8 (45 mg), and Day 15 (45 mg). From Cycle 2 onward, a single 45 mg dose is administered on Day 1 of each cycle. Treatment continues for up to 8 cycles (approximately 6 months).

Patients will be monitored for disease status according to standard clinical practice. After completing active treatment, they will enter a post-treatment follow-up phase.

Premedication with dexamethasone (20 mg) is mandatory in Cycle 1 and optional in later cycles. Acetaminophen and diphenhydramine may also be administered.

All patients will continue study treatment as per the Schedule of Activities or until premature discontinuation. After treatment discontinuation, disease status assessments will occur approximately every 3 months for up to 24 months. During post-treatment follow-up, PET-CT scans for disease evaluation will be performed every 6 months, as applicable. Patients not under active follow-up will be contacted annually to collect data on disease status and survival.

Throughout the trial, the following data will be collected (as applicable): demographics and baseline characteristics (including sex, age, race, height, and weight), medical history, details of initial diagnosis and treatment history, concomitant medications, adverse events (AEs), serious adverse events (SAEs), disease response, and survival status.

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • Fullicular Lymphoma-Previously Untreated Low Tumor Burden
  • Mosunetuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years old
  • confirmed classic FL (cFL) (according to WHO-HEAM4R classification)
  • Low tumor burden by GELF criteria
  • No prior therapy except surgery or radiotherapy for disease that was previously localized
  • Ann Arbor Stage III or IV disease
  • Bi-dimensionally measurable FDG-avid disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination
  • Adequate hematologic function defined as follows without growth factors or blood product transfusion within 14 days of first dose of study drug administration:

    1. , without transfusion, 9 g/dL
    2. 1.0 109/L
    3. count 75 109/L;
  • (ECOG) performance status 0 to 2
  • Patient can understand and sign the Form (ICF), can communicate with the Investigator, can understand and comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • 1. An active viral infection with virus (HBV) or virus (HCV) defined by detectable viral DNA in the blood by PCR. Patients with are eligible provided an undetectable viral load and a > 200 cell/mcl
  • 2. Any of the following laboratory abnormalities:

    1. Total or GGT or or ALT > 3 X .
    2. calculated by Cockcroft and Gault Formula \< 40 ml/min
  • Presence or history of CNS involvement by lymphoma
  • 4. Prior history of other than Lymphoma (except for Basal Cell or Squamous Cell Carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 2 years
  • to use Mosunetuzumabor known sensitivity or allergy
  • Pregnant or lactating females
  • 7. Female patients of who cannot or do not wish to use an effective method of , during the study treatment and for 3 months thereafter
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Patients with follicular lymphoma with low tumor burden who have not been previously treated

    In this study, Mosunetuzumab will be administered subcutaneously over 8 treatment cycles: 5 mg on Day 1 of Cycle 1, followed by 45 mg in all subsequent cycles.

    Drug: Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.

Interventions

  • DrugMosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.

    In this study, Mosunetuzumab will be administered subcutaneously over 8 treatment cycles: 5 mg on Day 1 of Cycle 1, followed by 45 mg in all subsequent cycles.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate-ORR Overall response rate (ORR) at the end of treatment (6 months) using the Lugano criteria

    ORR is defined as the proportion of patients who achieved Complete Response or Partial Response determined by Lugano 2014 criteria as assessed by investigators at 6 months after initiation of treatment and prior to the initiation of any subsequent anti-lymphoma therapy. Patients without post-baseline disease assessments will be considered non-responders.

    Time frame: 6 months

Secondary outcomes

  1. Progression Free Survival -PFS

    PFS is defined as the time in months from the first dose of study drug to disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. Surviving patients without disease progression will be censored at the time of the last adequate disease assessment. Surviving subjects without post-baseline disease assessment will be censored at the date of first dose of study drug.

    Time frame: up to 24 months after last treatment dose

  2. Duration of response -DOR

    DOR is defined for patients who achieved Complete Response (CR) or Partial Response (PR) ('responders'), as the time in months from initial CR/PR to disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. Surviving responders without radiographic disease progression will be censored at the time of the last adequate disease assessment

    Time frame: up to 24 months after last treatment dose

  3. Complete Response Rate - CRR - Lymphoma (FACT-Lym) subscale.

    CRR is defined as the proportion of patients who achieved Complete Response, determined by Lugano 2014 criteria as assessed by the investigator. All responses of Complete Response after initiation of subsequent anti-lymphoma therapy will be excluded. Subjects without post-baseline disease assessments will be considered as not achieving Complete Response.

    Time frame: up to 24 months after last treatment dose

  4. Duration of Complete Response -DOCR

    DOCR is defined for patients who achieved Complete Response, as the time in months from initial CR/PR to disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. Surviving responders without radiographic disease progression will be censored at the time of the last adequate disease assessment.

    Time frame: up to 24 months after last treatment dose

  5. Time to Next Treatment -TTNT

    TTNT is defined as the time from the date of the first dose of study drug to the start of new non-protocol-specified anti-lymphoma therapy or death due to disease progression. Surviving patients who were reported as not having started new non-protocol-specified anti-lymphoma therapy will be censored at the last known alive date to be free of non-protocol-specified anti-lymphoma therapy. Surviving patients without any post-baseline visit will be censored at the date of the first dose of study drug

    Time frame: up to 24 months after last treatment dose

  6. Overall Survival -OS

    OS is defined as the time in months from the first dose of study drug to death from any cause. Patients who are still alive at the end of the study or at the time of the analyses (12 and 24 months after the first dose of study drug) will be censored at the last known alive date

    Time frame: up to 24 months after last treatment dose

  7. Statistical Analysis for Safety

    Incidence of adverse events (AEs) and abnormal laboratory test results - including all AEs, treatment-emergent AEs (TEAEs), Adverse drug reactions (ADRs), SAEs, AEs leading to discontinuation, and AEs leading to death.

    Time frame: from first dose through 90 days after administration of last dose

  8. Health related quality of life

    Health-related quality of life will be assessed using the FACT-Lym (Functional Assessment of Cancer Therapy - Lymphoma) questionnaire.

    Time frame: whole treatment period- 6 months

Other outcomes

  1. Exploratory Biomarker Research Endpoints: Longitudinal measurement of ctDNA in the peripheral blood (PB), before and during treatment, at disease progression, at CR and one year after achievement of CR, as a biomarker for long-term remission

    Longitudinal measurement of ctDNA in the peripheral blood (PB), before and during treatment, at disease progression, at CR and one year after achievement of CR, as a biomarker for long-term remission;

    Time frame: up to one year after achievement CR

  2. Exploratory Biomarker Research Endpoints:

    Evaluating the treatment-induced dynamics and molecular signatures of the non-tumor lymphocytic and myeloid compartments in peripheral blood, before and during treatment, at disease progression, at CR and one year after achievement of CR by performing consecutive flow cytometry, single cell RNA sequencing (scRNA-seq) and epigenetic studies, and correlation with outcome;

    Time frame: up to year after achievement of CR

  3. Exploratory Biomarker Research Endpoints:

    Analyzing tumor microenvironment (TME) in lymph nodes pre-treatment at disease progression, at CR and one year after achievement of CR by performing scRNA-seq;

    Time frame: up to year after achievement of CR

  4. Exploratory Biomarker Research Endpoints

    Evaluating the association between patient's microbiome and response to treatment

    Time frame: 24 months after last treatment

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2028, 26 months after the start.

Of 151 non-industry phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 110. This study's planned 26 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartActual
Jan 5, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Mar 1, 2030
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07191249
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Jan 5, 2026
Primary completion
Apr 1, 2028 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Aug 11, 2026

Study contacts

Irit Avivi, Prof
Contact
iritavi@tlvmc.gov.il
+972 3-6974452
Irit Segalovich, B.Sc
Contact
iritseg@tlvmc.gov.il
+972 3-6947824
Irit Avivi, Prof
principal investigator · Tel-Aviv Sourasky Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion